JonesTrading analyst Soumit Roy has maintained their bullish stance on ACET stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Buy rating due to a combination of factors that highlight Adicet Bio’s potential for growth and innovation. The company is advancing its ADI-001 program, with initial data expected in the second half of 2025, which could provide significant insights into its efficacy for various inflammatory and autoimmune diseases. This program is currently enrolling patients with conditions such as lupus nephritis and systemic sclerosis, indicating a broad application potential.
Additionally, Adicet Bio is developing ADI-212, a promising candidate targeting prostate cancer, with plans to file an Investigational New Drug application by the first quarter of 2026. The company’s strategic decision to reduce its workforce by approximately 30% is aimed at extending its cash runway into the fourth quarter of 2026, reflecting prudent financial management. These factors, combined with the company’s strong cash position and the potential value of its technology, contribute to the Buy rating and the price target of $4.
According to TipRanks, Roy is an analyst with an average return of -23.6% and a 19.52% success rate. Roy covers the Healthcare sector, focusing on stocks such as Enliven Therapeutics, Nuvation Bio, and Prime Medicine, Inc..
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $8.00 price target.